Jacobs Levy Equity Management, Inc Vertex Pharmaceuticals Inc Transaction History

Jacobs Levy Equity Management, Inc

$24.7 Billion
Q3 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $161 Million - $192 Million	-468,612 Reduced 82.29%	100,868 $41 Million
Q3 2023 Nov 16, 2023	BUY	$338.18 - $362.46 $6.43 Million - $6.89 Million	19,010 Added 3.45%	569,480 $198 Million
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $22.6 Million - $25.3 Million	-71,944 Reduced 11.56%	550,470 $194 Million
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $3.85 Million - $4.39 Million	-13,578 Reduced 2.13%	622,414 $196 Million
Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $124 Million - $140 Million	434,318 Added 215.36%	635,992 $184 Million
Q3 2022 Nov 15, 2022	BUY	$273.83 - $305.53 $17 Million - $19 Million	62,213 Added 44.61%	201,674 $58.4 Million
Q2 2022 Aug 15, 2022	BUY	$234.96 - $292.55 $20.3 Million - $25.3 Million	86,428 Added 162.97%	139,461 $39.3 Million
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $3.93 Million - $4.64 Million	17,769 Added 50.39%	53,033 $13.8 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $74.7 Million - $94.3 Million	-421,858 Reduced 92.29%	35,264 $7.74 Million
Q3 2021 Nov 15, 2021	SELL	$181.39 - $202.99 $31.3 Million - $35.1 Million	-172,787 Reduced 27.43%	457,122 $82.9 Million
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $115 Million - $135 Million	612,225 Added 3462.03%	629,909 $127 Million
Q1 2021 May 17, 2021	SELL	$207.02 - $241.31 $23.7 Million - $27.7 Million	-114,685 Reduced 86.64%	17,684 $3.8 Million
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $20 Million - $26.6 Million	96,451 Added 268.53%	132,369 $31.3 Million
Q3 2020 Nov 16, 2020	SELL	$255.65 - $303.1 $4.72 Million - $5.6 Million	-18,465 Reduced 33.95%	35,918 $9.77 Million
Q2 2020 Aug 17, 2020	BUY	$225.48 - $295.8 $12.3 Million - $16.1 Million	54,383 New	54,383 $15.8 Million
Q2 2019 Aug 13, 2019	SELL	$164.61 - $190.37 $15.2 Million - $17.6 Million	-92,342 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$163.73 - $194.7 $37.7 Million - $44.8 Million	-230,348 Reduced 71.38%	92,342 $17 Million
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $10.3 Million - $13 Million	67,840 Added 26.62%	322,690 $53.5 Million
Q3 2018 Nov 14, 2018	BUY	$167.73 - $192.74 $5.04 Million - $5.79 Million	30,060 Added 13.37%	254,850 $49.1 Million
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $3.25 Million - $3.79 Million	22,320 Added 11.02%	224,790 $38.2 Million
Q1 2018 May 15, 2018	BUY	$151.6 - $177.13 $898,988 - $1.05 Million	5,930 Added 3.02%	202,470 $33 Million
Q4 2017 Feb 13, 2018	BUY	$137.28 - $155.55 $1.59 Million - $1.8 Million	11,590 Added 6.27%	196,540 $29.5 Million
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $1.35 Million - $1.48 Million	9,096 Added 5.17%	184,950 $28.1 Million
Q2 2017 Nov 09, 2017	BUY	N/A	175,854	175,854 $22.7 Million

Others Institutions Holding VRTX

# of Institutions

1,723

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

Capital World Investors Los Angeles, CA

26.8M
Shares

$12.1 Billion
1.99% of portfolio
Vanguard Group Inc Valley Forge, PA

23.2M
Shares

$10.4 Billion
0.2% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$9.61 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.8M
Shares

$5.33 Billion
0.23% of portfolio
Capital Research Global Investors Los Angeles, CA

9M
Shares

$4.06 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.

Account